Comparative Pharmacology
Head-to-head clinical analysis: SULFADIAZINE SODIUM versus SULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFADIAZINE SODIUM versus SULLA.
SULFADIAZINE SODIUM vs SULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfadiazine is a competitive inhibitor of dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydropteroate, thereby inhibiting bacterial folic acid synthesis.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
2-4 g IV initially, then 1-2 g IV every 6-8 hours; oral dose: 2-4 g loading, then 1-2 g every 6 hours
100 mg orally once daily, increased to 200 mg daily if needed.
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (prolonged in renal impairment; context: requires dose adjustment in CrCl <50 mL/min).
6-12 hours; prolonged in renal impairment (up to 30 hours)
Renal: 60-85% (via glomerular filtration and tubular secretion, with acetylation in liver reducing solubility and increasing crystalluria risk). Biliary/fecal: less than 15%. Unchanged drug and acetylated metabolites both excreted.
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Category D/X
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic